PTC Therapeutics Inc - Asset Resilience Ratio
PTC Therapeutics Inc (PTCT) has an Asset Resilience Ratio of 33.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PTCT liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how PTC Therapeutics Inc's Asset Resilience Ratio has changed over time. See PTC Therapeutics Inc (PTCT) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down PTC Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PTCT market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $960.72 Million | 33.0% |
| Total Liquid Assets | $960.72 Million | 33.00% |
Asset Resilience Insights
- Very High Liquidity: PTC Therapeutics Inc maintains exceptional liquid asset reserves at 33.00% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
PTC Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare PTC Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for PTC Therapeutics Inc (2004–2025)
The table below shows the annual Asset Resilience Ratio data for PTC Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 33.00% | $960.72 Million | $2.91 Billion | +11.89pp |
| 2024-12-31 | 21.11% | $359.99 Million | $1.71 Billion | +6.20pp |
| 2023-12-31 | 14.91% | $282.74 Million | $1.90 Billion | +7.24pp |
| 2022-12-31 | 7.67% | $130.87 Million | $1.71 Billion | -22.44pp |
| 2021-12-31 | 30.12% | $583.66 Million | $1.94 Billion | -10.41pp |
| 2020-12-31 | 40.52% | $894.84 Million | $2.21 Billion | +15.98pp |
| 2019-12-31 | 24.54% | $398.54 Million | $1.62 Billion | +19.35pp |
| 2018-12-31 | 5.19% | $58.09 Million | $1.12 Billion | -15.10pp |
| 2017-12-31 | 20.29% | $79.45 Million | $391.65 Million | -44.07pp |
| 2016-12-31 | 64.36% | $173.34 Million | $269.35 Million | -11.97pp |
| 2015-12-31 | 76.32% | $280.90 Million | $368.04 Million | -3.35pp |
| 2014-12-31 | 79.68% | $265.49 Million | $333.22 Million | -3.97pp |
| 2013-12-31 | 83.64% | $127.05 Million | $151.90 Million | +22.52pp |
| 2005-12-31 | 61.12% | $26.88 Million | $43.97 Million | -6.14pp |
| 2004-12-31 | 67.26% | $26.21 Million | $38.97 Million | -- |
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervo… Read more